Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. (Q46822051)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Rodrigo A. Bressan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Erik Arstad

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Kjell Erlandsson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Lisa Squassante

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Vincenzo Teneggi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

John H Krystal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Peter J Ell

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Lyn S Pilowsky

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

5 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

401-408

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18176855%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00213-007-1047-x

31 December 2019

exact match

0 references

cites work

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-007-1047-X

Effects of blood flow on [11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-007-1047-X

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-007-1047-X

Psychopathological consequences of ketamine.

21 January 2018

1 reference

12 December 2020

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

1 reference

12 December 2020

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

1 reference

12 December 2020

Synthesis and binding characteristics of N-(1-naphthyl)-N'-(3-[(125)I]-iodophenyl)-N'-methylguanidine ([(125)I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation

1 reference

12 December 2020

Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics

1 reference

12 December 2020

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

1 reference

12 December 2020

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

1 reference

12 December 2020

Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?

1 reference

12 December 2020

Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients

1 reference

12 December 2020

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

1 reference

12 December 2020

Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo.

1 reference

12 December 2020

Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.

1 reference

12 December 2020

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

1 reference

12 December 2020

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

1 reference

12 December 2020

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications

1 reference

12 December 2020

A systems model of altered consciousness: integrating natural and drug-induced psychoses

1 reference

12 December 2020

Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord.

1 reference

12 December 2020

A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261.

1 reference

12 December 2020

Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.

1 reference

12 December 2020

Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study

1 reference

12 December 2020

Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

1 reference

12 December 2020

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

1 reference

12 December 2020

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

1 reference

12 December 2020

The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).

1 reference

12 December 2020

NMDA receptor hypofunction model of schizophrenia

1 reference

12 December 2020

Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically

1 reference

12 December 2020

Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET.

1 reference

12 December 2020

Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale

1 reference

12 December 2020

Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor

1 reference

12 December 2020